Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval for their second antibody-drug conjugate (ADC) cancer treatment, Datroway, the partners have secured a seventh nod for their ...

Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive ...

Daiichi Sankyo has succeeded in a bid to convince the US Patent and Trademark Office (PTO) to take another look at a patent held by Seagen that was previously deemed to have been infringed by its ...

Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual ...

An AstraZeneca and Daiichi Sankyo drug designed to replace chemotherapy was cleared by US regulators for broader use in late-stage breast cancer patients. The Food and Drug Administration ...

Daiichi Sankyo, an innovative global healthcare company, has established a state-of-the-art research laboratory in San Diego, California, US, dedicated to the development of robotics, automation and ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

(RTTNews) - The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult ...

Daiichi Sankyo has claimed approval in Japan, its home market, for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd). It is the first global approval for the drug ...

Daiichi Sankyo Co. said on Friday it submitted its mRNA-based COVID-19 vaccine for regulatory approval in Japan. Approval would give Japan a home-grown mRNA vaccine of the type that have made up ...